Published in Oncogene on August 28, 2003
The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis. Proc Natl Acad Sci U S A (2006) 2.64
Knockdown of c-Myc expression by RNAi inhibits MCF-7 breast tumor cells growth in vitro and in vivo. Breast Cancer Res (2004) 1.52
Stanniocalcin 1 and ovarian tumorigenesis. J Natl Cancer Inst (2010) 1.33
Aurora kinase A promotes ovarian tumorigenesis through dysregulation of the cell cycle and suppression of BRCA2. Clin Cancer Res (2010) 1.31
Clearance of hepatitis B virus from the liver of transgenic mice by short hairpin RNAs. Proc Natl Acad Sci U S A (2005) 1.30
Two N-myristoyltransferase isozymes play unique roles in protein myristoylation, proliferation, and apoptosis. Mol Cancer Res (2005) 1.20
Transformation of human ovarian surface epithelial cells by Krüppel-like factor 8. Oncogene (2012) 1.08
Targeting the RAS oncogene. Expert Opin Ther Targets (2013) 1.02
Interleukin-1β promotes ovarian tumorigenesis through a p53/NF-κB-mediated inflammatory response in stromal fibroblasts. Neoplasia (2013) 0.98
Efficient RNA interference depends on global context of the target sequence: quantitative analysis of silencing efficiency using Eulerian graph representation of siRNA. Nucleic Acids Res (2004) 0.94
Small ribosomal protein subunit S7 suppresses ovarian tumorigenesis through regulation of the PI3K/AKT and MAPK pathways. PLoS One (2013) 0.93
A critical role for Rac1 in tumor progression of human colorectal adenocarcinoma cells. Am J Pathol (2007) 0.93
Proteomics analysis of H-RAS-mediated oncogenic transformation in a genetically defined human ovarian cancer model. Oncogene (2005) 0.86
Molecular mechanism of SLC5A8 inactivation in breast cancer. Mol Cell Biol (2013) 0.86
Fibrillin-1, induced by Aurora-A but inhibited by BRCA2, promotes ovarian cancer metastasis. Oncotarget (2015) 0.84
HER2 reduces breast cancer radiosensitivity by activating focal adhesion kinase in vitro and in vivo. Oncotarget (2016) 0.84
L1 retrotransposon-mediated stable gene silencing. Nucleic Acids Res (2005) 0.83
Overexpression of the β subunit of human chorionic gonadotropin promotes the transformation of human ovarian epithelial cells and ovarian tumorigenesis. Am J Pathol (2011) 0.82
Stanniocalicin 2 suppresses breast cancer cell migration and invasion via the PKC/claudin-1-mediated signaling. PLoS One (2015) 0.82
Targeting of the anti-apoptotic gene survivin in human thyroid carcinoma. Int J Mol Med (2012) 0.82
Epigenetic manipulation of gene expression: a toolkit for cell biologists. J Cell Biol (2005) 0.81
Allele-specific silencing of mutant p53 attenuates dominant-negative and gain-of-function activities. Oncotarget (2016) 0.76
New approaches for cancer treatment: antitumor drugs based on gene-targeted nucleic acids. Acta Naturae (2009) 0.75
Localization and Molecular Characterization of human Breast Cancer Initiating Cells from heterogeneous population of Breast Cancer Mesenchymal Stem cells by Immunofluorescence Microscopy. J Stem Cells Regen Med (2012) 0.75
A draft sequence of the rice genome (Oryza sativa L. ssp. indica). Science (2002) 42.78
Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell (2006) 10.10
The Genomes of Oryza sativa: a history of duplications. PLoS Biol (2005) 7.67
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med (2013) 6.70
The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell (2002) 6.05
The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers. Nat Med (2004) 4.69
Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther (2005) 3.27
Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clin Cancer Res (2005) 2.98
Atypical PKCiota contributes to poor prognosis through loss of apical-basal polarity and cyclin E overexpression in ovarian cancer. Proc Natl Acad Sci U S A (2005) 2.96
Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res (2004) 2.96
Structure and function of Nurr1 identifies a class of ligand-independent nuclear receptors. Nature (2003) 2.81
Structural basis of transcription activation: the CAP-alpha CTD-DNA complex. Science (2002) 2.67
The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis. Proc Natl Acad Sci U S A (2006) 2.64
KrasG12D-induced IKK2/β/NF-κB activation by IL-1α and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma. Cancer Cell (2012) 2.55
EGF-induced ERK activation promotes CK2-mediated disassociation of alpha-Catenin from beta-Catenin and transactivation of beta-Catenin. Mol Cell (2009) 2.50
Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell (2013) 2.34
Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol (2005) 2.34
Lineage infidelity of epithelial ovarian cancers is controlled by HOX genes that specify regional identity in the reproductive tract. Nat Med (2005) 2.30
Activated signal transducer and activator of transcription (STAT) 3: localization in focal adhesions and function in ovarian cancer cell motility. Cancer Res (2004) 2.24
Downregulation of XIAP and induction of apoptosis by the synthetic cyclin-dependent kinase inhibitor GW8510 in non-small cell lung cancer cells. Cancer Biol Ther (2006) 2.13
Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. Mol Carcinog (2008) 2.01
Intrinsic oxidative stress in cancer cells: a biochemical basis for therapeutic selectivity. Cancer Chemother Pharmacol (2003) 1.99
CDYL bridges REST and histone methyltransferases for gene repression and suppression of cellular transformation. Mol Cell (2008) 1.94
High level of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886). Cancer Biol Ther (2009) 1.86
Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer. Cancer Res (2007) 1.79
Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo. PLoS One (2010) 1.78
Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer. J Natl Cancer Inst (2013) 1.78
Nuclear expression of epidermal growth factor receptor is a novel prognostic value in patients with ovarian cancer. Mol Carcinog (2009) 1.71
Bax and Bak promote apoptosis by modulating endoplasmic reticular and mitochondrial Ca2+ stores. J Biol Chem (2001) 1.70
ALDH1 expression correlates with favorable prognosis in ovarian cancers. Mod Pathol (2009) 1.70
Oncogenic transformation confers a selective susceptibility to the combined suppression of the proteasome and autophagy. Mol Cancer Ther (2009) 1.69
Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation. Cancer (2008) 1.69
Correlation between CpG methylation profiles and hormone receptor status in breast cancers. Breast Cancer Res (2007) 1.68
Mitochondrial manganese-superoxide dismutase expression in ovarian cancer: role in cell proliferation and response to oxidative stress. J Biol Chem (2005) 1.64
Tissue macroarray: a simple and cost-effective method for high-throughput studies. Appl Immunohistochem Mol Morphol (2003) 1.61
Expression of several genes in the human chromosome 3p21.3 homozygous deletion region by an adenovirus vector results in tumor suppressor activities in vitro and in vivo. Cancer Res (2002) 1.61
Enhancing TRAIL-induced apoptosis by Bcl-X(L) siRNA. Cancer Biol Ther (2005) 1.61
Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells. J Natl Cancer Inst (2008) 1.61
REDD1 is required for RAS-mediated transformation of human ovarian epithelial cells. Cell Cycle (2009) 1.60
TGF-β modulates ovarian cancer invasion by upregulating CAF-derived versican in the tumor microenvironment. Cancer Res (2013) 1.56
Cancer-associated fibroblasts and their putative role in potentiating the initiation and development of epithelial ovarian cancer. Neoplasia (2011) 1.56
Expression of progesterone receptor is a favorable prognostic marker in ovarian cancer. Gynecol Oncol (2005) 1.56
The role of constitutively active signal transducer and activator of transcription 3 in ovarian tumorigenesis and prognosis. Cancer (2006) 1.55
Down-regulated expression of SATB2 is associated with metastasis and poor prognosis in colorectal cancer. J Pathol (2009) 1.53
Identification of a small molecule with synthetic lethality for K-ras and protein kinase C iota. Cancer Res (2008) 1.53
Activation of KLF8 transcription by focal adhesion kinase in human ovarian epithelial and cancer cells. J Biol Chem (2008) 1.52
Misregulated Wnt/beta-catenin signaling leads to ovarian granulosa cell tumor development. Cancer Res (2005) 1.51
Lack of p38 MAP kinase activation in TRAIL-resistant cells is not related to the resistance to TRAIL-mediated cell death. Cancer Biol Ther (2004) 1.49
Induction of papillary carcinoma in human ovarian surface epithelial cells using combined genetic elements and peritoneal microenvironment. Cell Cycle (2010) 1.48
Expression of multiple human endogenous retrovirus surface envelope proteins in ovarian cancer. Int J Cancer (2007) 1.48
Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence. Breast Cancer Res (2014) 1.46
Early detection of ovarian cancer: promise and reality. Cancer Treat Res (2002) 1.45
Vulvar Langerhans cell histiocytosis: a case report and review of the literature. Gynecol Oncol (2003) 1.43
CXCR2 promotes ovarian cancer growth through dysregulated cell cycle, diminished apoptosis, and enhanced angiogenesis. Clin Cancer Res (2010) 1.42
Activation of antioxidant pathways in ras-mediated oncogenic transformation of human surface ovarian epithelial cells revealed by functional proteomics and mass spectrometry. Cancer Res (2004) 1.41
MiR-182 overexpression in tumourigenesis of high-grade serous ovarian carcinoma. J Pathol (2012) 1.38
A critical role for I kappaB kinase alpha in the development of human and mouse squamous cell carcinomas. Proc Natl Acad Sci U S A (2006) 1.37
Design, synthesis, cytoselective toxicity, structure-activity relationships, and pharmacophore of thiazolidinone derivatives targeting drug-resistant lung cancer cells. J Med Chem (2008) 1.37
Bax-mediated Ca2+ mobilization promotes cytochrome c release during apoptosis. J Biol Chem (2002) 1.35
Lessons from border cell migration in the Drosophila ovary: A role for myosin VI in dissemination of human ovarian cancer. Proc Natl Acad Sci U S A (2004) 1.34
Stanniocalcin 1 and ovarian tumorigenesis. J Natl Cancer Inst (2010) 1.33
MiR-506 inhibits multiple targets in the epithelial-to-mesenchymal transition network and is associated with good prognosis in epithelial ovarian cancer. J Pathol (2014) 1.33
Crystal structures of IRAK-4 kinase in complex with inhibitors: a serine/threonine kinase with tyrosine as a gatekeeper. Structure (2006) 1.32
Molecular genetic evidence that endometriosis is a precursor of ovarian cancer. Int J Cancer (2006) 1.32
Putative tumor-suppressive function of Kruppel-like factor 4 in primary lung carcinoma. Clin Cancer Res (2009) 1.31
Aurora kinase A promotes ovarian tumorigenesis through dysregulation of the cell cycle and suppression of BRCA2. Clin Cancer Res (2010) 1.31
CD133 expression associated with poor prognosis in ovarian cancer. Mod Pathol (2011) 1.30
Bik/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitors. Oncogene (2005) 1.29
Assessment of two automated imaging systems in evaluating estrogen receptor status in breast carcinoma. Appl Immunohistochem Mol Morphol (2007) 1.29
Benign cystic mesothelioma of the peritoneum: a clinicopathologic study of 17 cases and immunohistochemical analysis of estrogen and progesterone receptor status. Hum Pathol (2003) 1.29
Inhibition of breast and ovarian tumor growth through multiple signaling pathways by using retrovirus-mediated small interfering RNA against Her-2/neu gene expression. J Biol Chem (2003) 1.27
HMGA2 overexpression-induced ovarian surface epithelial transformation is mediated through regulation of EMT genes. Cancer Res (2011) 1.27
Cyclin E expression is correlated with tumor progression and predicts a poor prognosis in patients with ovarian carcinoma. Cancer (2006) 1.25
STAT3 mediates resistance to MEK inhibitor through microRNA miR-17. Cancer Res (2011) 1.24
OSW-1: a natural compound with potent anticancer activity and a novel mechanism of action. J Natl Cancer Inst (2005) 1.23
Centrosome-associated regulators of the G(2)/M checkpoint as targets for cancer therapy. Mol Cancer (2009) 1.23
WWOX protein expression varies among ovarian carcinoma histotypes and correlates with less favorable outcome. BMC Cancer (2005) 1.22
Synergistic tumor suppression by coexpression of FHIT and p53 coincides with FHIT-mediated MDM2 inactivation and p53 stabilization in human non-small cell lung cancer cells. Cancer Res (2004) 1.22
Validation of tissue microarray technology in ovarian carcinoma. Mod Pathol (2004) 1.22
Expression of the tumor suppressor gene ARHI in epithelial ovarian cancer is associated with increased expression of p21WAF1/CIP1 and prolonged progression-free survival. Clin Cancer Res (2004) 1.22
Loss of the expression of the tumor suppressor gene ARHI is associated with progression of breast cancer. Clin Cancer Res (2003) 1.22
CD44 expression is a feature of prostatic small cell carcinoma and distinguishes it from its mimickers. Hum Pathol (2008) 1.21
Metabolic shifts toward glutamine regulate tumor growth, invasion and bioenergetics in ovarian cancer. Mol Syst Biol (2014) 1.21
Long-term tumor-free survival from treatment with the GFP-TRAIL fusion gene expressed from the hTERT promoter in breast cancer cells. Oncogene (2002) 1.20
Subcellular localization of p27kip1 expression predicts poor prognosis in human ovarian cancer. Clin Cancer Res (2005) 1.20
The biphasic role of NF-kappaB in progression and chemoresistance of ovarian cancer. Clin Cancer Res (2011) 1.19
Comprehensive assessment of heavy metal contamination in sediment of the Pearl River Estuary and adjacent shelf. Mar Pollut Bull (2012) 1.19
Molecular basis of sphingosine kinase 1 substrate recognition and catalysis. Structure (2013) 1.18
Treatment of radioresistant stem-like esophageal cancer cells by an apoptotic gene-armed, telomerase-specific oncolytic adenovirus. Clin Cancer Res (2008) 1.18
Aberrant expression of proteins involved in signal transduction and DNA repair pathways in lung cancer and their association with clinical parameters. PLoS One (2012) 1.17
Lysophosphatidic acid production and action: validated targets in cancer? J Cell Biochem (2004) 1.17
Mucinous adenocarcinoma developed from human fallopian tube epithelial cells through defined genetic modifications. Cell Cycle (2012) 1.16
Paris saponin II of Rhizoma Paridis--a novel inducer of apoptosis in human ovarian cancer cells. Biosci Trends (2012) 1.15
The differential role of L1 in ovarian carcinoma and normal ovarian surface epithelium. Cancer Res (2008) 1.14
Novel role of NOX in supporting aerobic glycolysis in cancer cells with mitochondrial dysfunction and as a potential target for cancer therapy. PLoS Biol (2012) 1.14
Biological significance of prolactin in gynecologic cancers. Cancer Res (2009) 1.13
The p.Ser267Phe variant in SLC10A1 is associated with resistance to chronic hepatitis B. Hepatology (2015) 1.12
Ovarian sex cord-stromal tumors: an immunohistochemical study including a comparison of calretinin and inhibin. Mod Pathol (2003) 1.12